Interferón alfa 2b recombinante más ribavirina en el tratamiento de la hepatitis crónica C

Sánchez Rodríguez, Yoan Antonio; Arús Soler, Enrique; Grá Oramas, Bienvenido; López Saura, Pedro; Nodarse Cuní, Hugo.
Rev. cuba. med ; 49(2)abr.-jun. 2010. graf
Artículo en Español | CUMED | ID: cum-50445

Documentos relacionados

  1. Interferón alfa 2b recombinante más ribavirina en el tratamiento de la hepatitis crónica C
  2. Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a.
  3. [Precise immunological classification guidance for early initiation of antiviral therapy in patients with chronic HBV infection].
  4. Pharmacological interventions for acute hepatitis C infection.
  5. [Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C].
  6. The Severity of Depressive Symptoms as an Independent Predictor of Sustained Virological Response During Treatment of Hepatitis C With Pegylated Interferon-α2a and Oral Ribavirin.
  7. Inhibiting cell-to-cell transmission to reach HDV cure: The importance of IFN-α.
  8. Histomorphometric Findings May Help Predicting Response in Patients with Chronic Liver Disease.
  9. COMBINED ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS INFECTION WITH PEGYLATED INTERFERON (PEG-IFN) Α-2A (PEGFERON) AND RIBAVIRIN (COPEGUS) IN INMATES.
  10. Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease.